Cancer Drug Resistance

Research advances and new challenges in overcoming triple-negative breast cancer

Yu Zong, Mark Pegram

View Full-Text Download PDF

Page 517-542
Emerging RAS-directed therapies for cancer

Michael Conroy, Darren Cowzer, Walter Kolch, Austin G. Duffy

View Full-Text Download PDF

Page 543-558
The implication of liquid biopsies to predict chemoresistance in pancreatic cancer

Elisabetta Pietri, Rita Balsano, Matilde Coriano, Fabio Gelsomino, Francesco Leonardi, Simona Bui, Letizia Gnetti, Raffaele Dalla Valle, Ingrid Garajová

View Full-Text Download PDF

Page 559-572
Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer

Natasha Rinne, Elizabeth L. Christie, Anastasia Ardasheva, Chun Hei Kwok, Nikita Demchenko, Caroline Low, Catherine Tralau-Stewart, Christina Fotopoulou, Paula Cunnea

View Full-Text Download PDF

Page 573-595
Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy

Alice Romagnoli, Cristina Maracci, Mattia D’Agostino, Anna La Teana, Daniele Di Marino

View Full-Text Download PDF

Page 596-606
Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment

John K. Cowell, Tianxiang Hu

View Full-Text Download PDF

Page 607-619
ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an in vivo model

Jordan M. Hotz, Joanna R. Thomas, Emily N. Katz, Robert W. Robey, Sachi Horibata, Michael M. Gottesman

View Full-Text Download PDF

Page 620-633
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Kyung Bo Kim

View Full-Text Download PDF

Page 634-645
Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment

Sanam Shahid, Susan E. Prockop

View Full-Text Download PDF

Page 646-664
Drug resistance in targeted cancer therapies with RAF inhibitors

Ufuk Degirmenci, Jiajun Yap, Yuen Rong M. Sim, Shiru Qin, Jiancheng Hu

View Full-Text Download PDF

Page 665-683
Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer

Haiyun Zhang, Alexander Steed, Milo Co, Xiaozhuo Chen

View Full-Text Download PDF

Page 684-709
Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

Jean-Marie Michot, Alice Buet-Elfassy, Maxime Annereau, Julien Lazarovici, Alina Danu, Clémentine Sarkozy, Claude Chahine, Camille Bigenwald, Jacques Bosq, Julien Rossignol, Patricia Romano-Martin, Capucine Baldini, David Ghez, Peggy Dartigues, Christophe Massard, Vincent Ribrag

View Full-Text Download PDF

Page 710-718
Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro

I.V. Bijnsdorp, Godefridus J. Peters

View Full-Text Download PDF

Page 719-727
Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Xin Yu, Xiangling Chu, Yan Wu, Juan Zhou, Jing Zhao, Fei Zhou, Chaonan Han, Chunxia Su

View Full-Text Download PDF

Page 728-739
Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer

Jacopo Giuliani, Andrea Bonetti

View Full-Text Download PDF

Page 740-744

Hot Keywords

Table of Contents (15 articles)

Research advances and new challenges in overcoming triple-negative breast cancer

Emerging RAS-directed therapies for cancer

The implication of liquid biopsies to predict chemoresistance in pancreatic cancer

Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer

Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment

ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an in vivo model

Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment

Drug resistance in targeted cancer therapies with RAF inhibitors

Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer

Actions for selected articles

CANCER DRUG RESISTANCE

Navigation

follow us

OAE Publishing Inc.

OAE JOURNALS

FOLLOW OAE